vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and TRANSACT TECHNOLOGIES INC (TACT). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $11.5M, roughly 1.4× TRANSACT TECHNOLOGIES INC). On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 11.9%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 3.5%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
DERM vs TACT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $11.5M |
| Net Profit | $-1.2M | — |
| Gross Margin | — | 47.6% |
| Operating Margin | -2.8% | -10.1% |
| Net Margin | -7.8% | — |
| Revenue YoY | 27.3% | 11.9% |
| Net Profit YoY | -182.0% | — |
| EPS (diluted) | $-0.04 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $11.5M | ||
| Q3 25 | $17.0M | $13.2M | ||
| Q2 25 | $15.0M | $13.8M | ||
| Q1 25 | $13.1M | $13.1M | ||
| Q4 24 | $12.6M | $10.2M | ||
| Q3 24 | $14.6M | $10.9M | ||
| Q2 24 | $14.9M | $11.6M | ||
| Q1 24 | $13.0M | $10.7M |
| Q4 25 | $-1.2M | — | ||
| Q3 25 | $-2.3M | $15.0K | ||
| Q2 25 | $-3.8M | $-143.0K | ||
| Q1 25 | $-4.1M | $19.0K | ||
| Q4 24 | $1.5M | — | ||
| Q3 24 | $-2.4M | $-551.0K | ||
| Q2 24 | $-3.4M | $-319.0K | ||
| Q1 24 | $-10.4M | $-1.0M |
| Q4 25 | — | 47.6% | ||
| Q3 25 | — | 49.8% | ||
| Q2 25 | — | 48.2% | ||
| Q1 25 | — | 48.7% | ||
| Q4 24 | 82.3% | 44.2% | ||
| Q3 24 | 63.9% | 48.1% | ||
| Q2 24 | 56.0% | 52.7% | ||
| Q1 24 | 47.7% | 52.6% |
| Q4 25 | -2.8% | -10.1% | ||
| Q3 25 | -9.0% | 0.1% | ||
| Q2 25 | -19.2% | -1.9% | ||
| Q1 25 | -25.3% | -0.1% | ||
| Q4 24 | 17.7% | -10.3% | ||
| Q3 24 | -19.8% | -7.7% | ||
| Q2 24 | -19.7% | -3.8% | ||
| Q1 24 | -77.4% | -12.2% |
| Q4 25 | -7.8% | — | ||
| Q3 25 | -13.6% | 0.1% | ||
| Q2 25 | -25.3% | -1.0% | ||
| Q1 25 | -31.0% | 0.1% | ||
| Q4 24 | 12.1% | — | ||
| Q3 24 | -16.3% | -5.1% | ||
| Q2 24 | -22.6% | -2.8% | ||
| Q1 24 | -80.1% | -9.7% |
| Q4 25 | $-0.04 | $-0.11 | ||
| Q3 25 | $-0.09 | $0.00 | ||
| Q2 25 | $-0.16 | $-0.01 | ||
| Q1 25 | $-0.18 | $0.00 | ||
| Q4 24 | $0.10 | $-0.80 | ||
| Q3 24 | $-0.12 | $-0.06 | ||
| Q2 24 | $-0.17 | $-0.03 | ||
| Q1 24 | $-0.53 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $20.4M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $31.1M |
| Total Assets | $94.6M | $44.8M |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $20.4M | ||
| Q3 25 | $24.9M | $20.0M | ||
| Q2 25 | $20.3M | $17.7M | ||
| Q1 25 | $21.1M | $14.2M | ||
| Q4 24 | $20.3M | $14.4M | ||
| Q3 24 | $22.5M | $11.3M | ||
| Q2 24 | $23.9M | $11.1M | ||
| Q1 24 | $24.1M | $10.6M |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $31.1M | ||
| Q3 25 | $25.9M | $31.8M | ||
| Q2 25 | $19.2M | $31.3M | ||
| Q1 25 | $21.5M | $30.9M | ||
| Q4 24 | $20.1M | $30.6M | ||
| Q3 24 | $10.9M | $38.4M | ||
| Q2 24 | $11.3M | $38.5M | ||
| Q1 24 | $13.0M | $38.6M |
| Q4 25 | $94.6M | $44.8M | ||
| Q3 25 | $85.2M | $45.0M | ||
| Q2 25 | $81.2M | $44.5M | ||
| Q1 25 | $85.0M | $44.2M | ||
| Q4 24 | $80.2M | $44.0M | ||
| Q3 24 | $64.0M | $50.5M | ||
| Q2 24 | $65.2M | $50.4M | ||
| Q1 24 | $66.6M | $51.9M |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $609.0K |
| Free Cash FlowOCF − Capex | — | $589.0K |
| FCF MarginFCF / Revenue | — | 5.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $7.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $609.0K | ||
| Q3 25 | $-2.4M | $3.6M | ||
| Q2 25 | $-942.0K | $3.6M | ||
| Q1 25 | $-2.8M | $-161.0K | ||
| Q4 24 | $2.2M | $2.4M | ||
| Q3 24 | $-1.2M | $327.0K | ||
| Q2 24 | $-5.2M | $636.0K | ||
| Q1 24 | $-5.0M | $-1.5M |
| Q4 25 | — | $589.0K | ||
| Q3 25 | — | $3.6M | ||
| Q2 25 | — | $3.6M | ||
| Q1 25 | — | $-171.0K | ||
| Q4 24 | — | $2.4M | ||
| Q3 24 | — | $259.0K | ||
| Q2 24 | — | $499.0K | ||
| Q1 24 | — | $-1.6M |
| Q4 25 | — | 5.1% | ||
| Q3 25 | — | 27.1% | ||
| Q2 25 | — | 25.9% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | 23.2% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 4.3% | ||
| Q1 24 | — | -14.9% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 0.6% | ||
| Q2 24 | — | 1.2% | ||
| Q1 24 | — | 1.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 242.00× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -8.47× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
TACT
Segment breakdown not available.
